Analyst Summary:
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, reported net revenues of $43.1 million and positive non-GAAP operating income1 for Q4 2022. The company reported strong market share gains in the US market and expects to grow twice as fast as the US market in 2023. Furthermore, Evolus expects to achieve positive non-GAAP operating income by Q4 2023 without additional capital. The company also plans to expand its reach in European countries and Australia. However, investors should be cautious, as the forward-looking statements include potential risks and uncertainties that can cause actual results to differ materially from the forward-looking statements.
Quotes:
"was the fastest-growing neurotoxin in the U. S aesthetic market, crossing into a double-digit unit share position. leading to the presentation earlier this year of very encouraging interim data." - David Moatazedi, President and Chief Executive Officer.
Forward-Looking Statements:
The company expects to achieve positive non-GAAP operating income by Q4 2023 without additional capital. The company also plans to expand its reach in European countries and Australia. However, the forward-looking statements include potential risks and uncertainties that can cause actual results to differ materially from the forward-looking statements.